There has been a lot of media attention on the issue of transvaginal mesh implants lately, and more and more women have become aware of the implications of using this surgical implant. In 2008, the FDA issued a notice informing the public of the growing number of complications being reported. They issued an update in 2011 notifying the public that the condition POP can be treated successfully without mesh, therefore avoiding the risk complications that are mesh-related but that announcement...Continue Reading
Over the past decade, there has been a growing debate over the risks associated with inferior vena cava filters, commonly known as IVC filters. These filters are implanted in patients who suffer from blood clot complications to reduce the risk of pulmonary embolism, blood clots and deep vein thrombosis. However, studies have shown that extended retention of IVC filters in the body may increase the risk of blood clot as well as injury to organs. What is an IVC filter?...Continue Reading
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a group of FDA-approved drugs used to treat low blood sugar in adults suffering from Type-2 diabetes. However, in 2015, the FDA issued a warning that Invokana and other SGLT2 inhibitors can trigger a condition known as diabetic ketoacidosis (DKA). This condition is caused by very high levels of acid in blood. In addition, the FDA has also warned that SGLT2 inhibitors can cause kidney injuries, bone fractures, breast and bladder cancer and pancreatitis among...Continue Reading
Doctors find certain diabetes drugs can increase the chance for potentially fatal acidic blood condition. In a June 8, 2017 correspondence to the New England Journal of Medicine, doctors associated with Harvard Medical School wrote that SGLT2 inhibitors, a class of type 2 diabetes drugs that includes Invokana and Invokamet, can double the risk of diabetic ketoacidosis when compared to DPP4 inhibitors, a different kind of diabetes drug. The researchers identified patients who had recently started treatment of their diabetes...Continue Reading
Trials find the drug doubles the risk of leg and foot amputation In a recent communication, the U.S. Food and Drug Administration (FDA) warned patients that taking the type 2 diabetes drug canagliflozin (Invokana, Invokamet, Invokamet XR) can cause an increased risk of leg and foot amputations. The FDA says patients taking Invokana and similar drugs should notify their doctor as soon as possible if they find new pain and tenderness in their feet and legs. Invokana and Invokamet are...Continue Reading
Speak with a Lawyer
Contact an attorney today for a free and confidential legal consultation.